晚期非小细胞肺癌免疫治疗耐药寡进展的治疗

Treatment of oligoprogression to immunotherapy resistance in advanced non-small cell lung cancer

近年来,肺癌的发病率逐年上升,驱动基因阴性的晚期非小细胞肺癌传统治疗临床效果较为有限,免疫检查点抑制剂(immune checkpoint inhibitor,ICI)的临床应用极大地改变了晚期非小细胞肺癌患者的治疗格局,然而多数患者仍不可避免地出现原发性耐药或获得性耐药,寡进展是获得性耐药的主要进展模式之一。因此,进一步认识免疫治疗耐药后寡进展的治疗措施至关重要,本文旨在对免疫治疗出现寡进展之后的治疗进行系统性的综述。

In recent years,the incidence of lung cancer has been increasing year by year.Traditional treatments have limited clinical effects in advanced,driver-gene-negative non-small cell lung cancer.Immune checkpoint inhibitors(ICI)have dramatically changed the treatment landscape of advanced non-small cell lung cancer.However,most patients are suffered from primary and acquired resistance inevitably.Oligoprogression is one of the main progression patterns of acquired resistance.Therefore,it is essential to further understand treatment of oligoprogression to immunotherapy resistance.This article aimed to conduct a systematic review of the treatment of oligoprogression to immunotherapy resistance.